$650,000.00 in Sales Expected for Mediwound Ltd (MDWD) This Quarter

Equities research analysts expect Mediwound Ltd (NASDAQ:MDWD) to announce $650,000.00 in sales for the current fiscal quarter, Zacks reports. Three analysts have made estimates for Mediwound’s earnings, with the highest sales estimate coming in at $700,000.00 and the lowest estimate coming in at $540,000.00. Mediwound reported sales of $430,000.00 during the same quarter last year, which would suggest a positive year-over-year growth rate of 51.2%. The company is scheduled to announce its next earnings report on Tuesday, February 20th.

On average, analysts expect that Mediwound will report full-year sales of $650,000.00 for the current fiscal year, with estimates ranging from $2.51 million to $2.61 million. For the next financial year, analysts expect that the company will post sales of $5.93 million per share, with estimates ranging from $3.80 million to $9.83 million. Zacks’ sales calculations are a mean average based on a survey of research firms that follow Mediwound.

Mediwound (NASDAQ:MDWD) last posted its quarterly earnings results on Thursday, November 16th. The biopharmaceutical company reported ($0.16) EPS for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.03. Mediwound had a negative net margin of 904.26% and a negative return on equity of 246.58%.

A number of research firms recently commented on MDWD. Oppenheimer set a $10.00 price target on shares of Mediwound and gave the stock a “buy” rating in a report on Thursday, November 16th. Zacks Investment Research cut shares of Mediwound from a “hold” rating to a “sell” rating in a report on Thursday, January 18th. ValuEngine raised shares of Mediwound from a “strong sell” rating to a “sell” rating in a report on Friday, October 20th. Finally, SunTrust Banks set a $9.00 price target on shares of Mediwound and gave the stock a “buy” rating in a report on Thursday, November 16th. Two research analysts have rated the stock with a sell rating and five have given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average price target of $9.13.

Shares of Mediwound (NASDAQ MDWD) opened at $4.20 on Friday. The company has a market cap of $109.54, a P/E ratio of -4.29 and a beta of 0.01. Mediwound has a 1-year low of $3.56 and a 1-year high of $8.25.

Several institutional investors and hedge funds have recently added to or reduced their stakes in MDWD. Harel Insurance Investments & Financial Services Ltd. grew its position in shares of Mediwound by 5,084.4% during the 4th quarter. Harel Insurance Investments & Financial Services Ltd. now owns 754,434 shares of the biopharmaceutical company’s stock valued at $3,357,000 after purchasing an additional 739,882 shares in the last quarter. Alyeska Investment Group L.P. purchased a new position in shares of Mediwound during the 3rd quarter valued at $2,140,000. Nationwide Fund Advisors purchased a new position in shares of Mediwound during the 3rd quarter valued at $1,538,000. Migdal Insurance & Financial Holdings Ltd. grew its position in shares of Mediwound by 9.5% during the 3rd quarter. Migdal Insurance & Financial Holdings Ltd. now owns 2,220,972 shares of the biopharmaceutical company’s stock valued at $11,882,000 after purchasing an additional 192,860 shares in the last quarter. Finally, Wells Fargo & Company MN grew its position in shares of Mediwound by 84.6% during the 4th quarter. Wells Fargo & Company MN now owns 101,189 shares of the biopharmaceutical company’s stock valued at $450,000 after purchasing an additional 46,366 shares in the last quarter. Hedge funds and other institutional investors own 29.46% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This piece was originally posted by American Banking News and is the property of of American Banking News. If you are viewing this piece on another domain, it was illegally copied and republished in violation of United States & international trademark & copyright legislation. The correct version of this piece can be accessed at https://www.americanbankingnews.com/2018/02/09/650000-00-in-sales-expected-for-mediwound-ltd-mdwd-this-quarter.html.

Mediwound Company Profile

MediWound Ltd. is a biopharmaceutical company. The Company focuses on developing, manufacturing and commercializing therapeutics products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The Company’s product, NexoBrid, is indicated for the removal of dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns, also referred to as severe burns.

Get a free copy of the Zacks research report on Mediwound (MDWD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Mediwound (NASDAQ:MDWD)

Receive News & Ratings for Mediwound Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mediwound and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply